Clinical Drug Experience Knowledgebase

Criteria

Inclusion Criteria:

Age >=18 years.
Histological or cytological documentation of non hematologic, malignant solid tumour.
Have failed at least one previous therapeutic regimen.
Measurable disease according to RECIST 1.1.
Life expectancy >= 12 weeks
ECOG Performance Status of 0 or 1
Written, signed and dated informed consent
Able and willing to meet all protocol-required treatments, investigations and visits.
Have adequate organ function

Exclusion Criteria:

Clinically significant non-malignant disease.
Active CNS metastases.
Subjects with uncontrolled diabetes.
History of clinically significant adverse drug reaction to heparin or other anti-coagulant agents
History of immune-mediated thrombocytopaenia or other platelet abnormalities or other hereditary or acquired coagulopathies.
Concomitant use of aspirin (> 150 mg/day), NSAIDs (except COX-2 selective inhibitors), vitamin K antagonists (other than low-dose prophylactic use), heparin within two weeks prior to randomisation, or other anti-platelet drugs.
History of severe allergic, anaphylactic or other significant adverse reaction to radiographic contrast media
Known seropositivity to the human immunodeficiency virus (HIV)
Women who are pregnant or breast-feeding.
Women of child-bearing potential and male subjects who are partners of women of childbearing potential who are unable or unwilling to practice a highly effective means of contraception.
Active substance abuse
Subjects who have received an investigational agent within 28 days prior to Cycle 1 Day 1.